CureVac N.V.(CVAC)Earnings, Financials & Key Ratios
CVAC•NASDAQ
6.5× P/E·Price updated Apr 24, 2026
AboutCureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.Show more
- Revenue$535M+895.5%
- EBITDA$196M+178.3%
- Net Income$162M+162.3%
- EPS (Diluted)0.72+161.0%
- Gross Margin80.23%+161.1%
- EBITDA Margin36.71%+107.9%
- Operating Margin33.2%+106.5%
- Net Margin30.3%+106.3%
- ROE26.73%+153.9%
CVAC Key Insights
CureVac N.V. (CVAC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 15.6% free cash flow margin
- ✓Strong 5Y sales CAGR of 98.4%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CVAC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CVAC Price & Volume
CureVac N.V. (CVAC) stock price & volume — 10-year historical chart
Loading chart...
CVAC Growth Metrics
CureVac N.V. (CVAC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years98.39%
3 Years73.21%
TTM682.03%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM170.11%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM170.73%
Return on Capital
10 Years-40.1%
5 Years-21.31%
3 Years-16.16%
Last Year26.67%
CVAC Recent Earnings
CureVac N.V. (CVAC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 4/12 qtrs (36%)
Q4 2025Latest
Nov 24, 2025Metric
Actual
Est
EPS
$0.10+41.2%
$0.17
Rev
$573M
—
Q3 2025
Aug 15, 2025Metric
Actual
Est
EPS
$0.30-66.7%
$0.18
Rev
$1M-62.7%
$4M
Q2 2025
May 20, 2025Metric
Actual
Est
EPS
$0.24-50.0%
$0.16
Rev
$978,951-79.7%
$5M
Q2 2025
Apr 10, 2025Metric
Actual
Est
EPS
$0.15+31.8%
$0.22
Rev
$15M+122.7%
$7M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 24, 2025 | $0.10vs $0.17+41.2% | $573M |
| Q3 2025 | Aug 15, 2025 | $0.30vs $0.18-66.7% | $1Mvs $4M-62.7% |
| Q2 2025 | May 20, 2025 | $0.24vs $0.16-50.0% | $978,951vs $5M-79.7% |
| Q2 2025 | Apr 10, 2025 | $0.15vs $0.22+31.8% | $15Mvs $7M+122.7% |
Based on last 12 quarters of dataView full earnings history →
CVAC Peer Comparison
CureVac N.V. (CVAC) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MRNA | 25.37B | 63.96 | -8.81 | -39.23% | -143.55% | -36.73% | 0.22 | |
 BNTX | 22.98B | 90.89 | -17.51 | 0.2% | -39.6% | -6.03% | 0.01 | |
 ARCT | 214.03M | 7.53 | -3.14 | -51.43% | -173.47% | -36.55% | 0.12 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare CVAC vs Peers
CureVac N.V. (CVAC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CVAC Income Statement
CureVac N.V. (CVAC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 12.87M | 17.42M | 48.9M | 102.99M | 67.42M | 53.76M | 535.18M | 510.51M |
Revenue Growth % | - | 35.31% | 180.78% | 110.61% | -34.54% | -20.26% | 895.54% | 682.03% |
Cost of Goods Sold | 17.74M | 27.98M | 14.17M | 238.19M | 183.99M | 124.37M | 105.83M | 26.5M |
COGS % of Revenue | 137.86% | 160.67% | 28.98% | 231.28% | 272.91% | 231.34% | 19.77% | - |
Gross Profit | -4.87M▲ 0% | -10.57M▼ 116.8% | 34.73M▲ 428.6% | -135.21M▼ 489.3% | -116.57M▲ 13.8% | -70.61M▲ 39.4% | 429.35M▲ 708.1% | 484M▲ 0% |
Gross Margin % | -37.86% | -60.67% | 71.02% | -131.28% | -172.91% | -131.34% | 80.23% | 94.81% |
Gross Profit Growth % | - | -116.85% | 428.64% | -489.34% | 13.78% | 39.43% | 708.08% | - |
Operating Expenses | 67.95M | 88.93M | 158.7M | 277.06M | 134.28M | 203.6M | 251.67M | 275.86M |
OpEx % of Revenue | 527.94% | 510.62% | 324.54% | 269.01% | 199.17% | 378.73% | 47.03% | - |
Selling, General & Admin | 21.5M | 43.94M | 45.76M | 88.94M | 89.41M | 76.43M | 74.33M | 72.88M |
SG&A % of Revenue | 167.04% | 252.29% | 93.58% | 86.36% | 132.62% | 142.18% | 13.89% | - |
Research & Development | 41.72M | 43.24M | 113.81M | 815.91M | 62.55M | 115.72M | 153.03M | 166.59M |
R&D % of Revenue | 324.16% | 248.29% | 232.74% | 792.22% | 92.78% | 215.27% | 28.59% | - |
Other Operating Expenses | 4.73M | 1.75M | -870K | -627.79M | -17.68M | 11.44M | 24.3M | 696K |
Operating Income | -72.82M▲ 0% | -99.5M▼ 36.6% | -124M▼ 24.6% | -412.26M▼ 232.5% | -249.46M▲ 39.5% | -274.21M▼ 9.9% | 177.68M▲ 164.8% | 208.15M▲ 0% |
Operating Margin % | -565.8% | -571.3% | -253.58% | -400.29% | -370% | -510.08% | 33.2% | 40.77% |
Operating Income Growth % | - | -36.63% | -24.63% | -232.46% | 39.49% | -9.92% | 164.8% | - |
EBITDA | -68.94M | -94.74M | -110.39M | -376.38M | -223.3M | -250.82M | 196.49M | 225.95M |
EBITDA Margin % | -535.6% | -543.96% | -225.75% | -365.46% | -331.2% | -466.57% | 36.71% | 44.26% |
EBITDA Growth % | - | -37.42% | -16.52% | -240.96% | 40.67% | -12.33% | 178.34% | 185.02% |
D&A (Non-Cash Add-back) | 3.89M | 4.76M | 13.61M | 35.88M | 26.16M | 23.39M | 18.81M | 17.8M |
EBIT | -70.86M | -98.67M | -107.75M | -402.16M | -245.45M | -257.48M | 190.88M | 220.79M |
Net Interest Income | 1.69M | -627K | -20.03M | -235K | 302K | 14.24M | 12.36M | 11.4M |
Interest Income | 1.97M | 833K | 2.07M | 10.1M | 4.01M | 16.73M | 12.36M | 11.8M |
Interest Expense | 275K | 1.46M | 22.1M | 10.34M | 3.71M | 2.49M | 0 | 403K |
Other Income/Expense | 1.69M | -627K | -20.03M | -235K | 302K | 14.24M | 13.2M | 12.24M |
Pretax Income | -71.13M▲ 0% | -100.13M▼ 40.8% | -129.8M▼ 29.6% | -412.5M▼ 217.8% | -249.16M▲ 39.6% | -259.97M▼ 4.3% | 190.88M▲ 173.4% | 220.39M▲ 0% |
Pretax Margin % | -552.65% | -574.9% | -265.44% | -400.52% | -369.56% | -483.59% | 35.67% | 43.17% |
Income Tax | 110K | -252K | -726K | -782K | -126K | 198K | 28.7M | 26.75M |
Effective Tax Rate % | -0.15% | 0.25% | 0.56% | 0.19% | 0.05% | -0.08% | 15.03% | 12.14% |
Net Income | -71.24M▲ 0% | -99.87M▼ 40.2% | -129.07M▼ 29.2% | -411.72M▼ 219.0% | -249.03M▲ 39.5% | -260.17M▼ 4.5% | 162.19M▲ 162.3% | 193.64M▲ 0% |
Net Margin % | -553.5% | -573.46% | -263.95% | -399.76% | -369.37% | -483.96% | 30.3% | 37.93% |
Net Income Growth % | - | -40.19% | -29.24% | -218.98% | 39.51% | -4.47% | 162.34% | 170.11% |
Net Income (Continuing) | -71.24M | -99.87M | -129.12M | -411.72M | -249.03M | -260.17M | 162.19M | 193.64M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.40▲ 0% | -0.53▼ 32.5% | -0.98▼ 84.9% | -2.21▼ 125.5% | -1.32▲ 40.3% | -1.18▲ 10.6% | 0.72▲ 161.0% | 0.86▲ 0% |
EPS Growth % | - | -32.5% | -84.91% | -125.51% | 40.27% | 10.61% | 161.02% | 170.73% |
EPS (Basic) | -0.40 | -0.53 | -0.98 | -2.21 | -1.32 | -1.18 | 0.72 | - |
Diluted Shares Outstanding | 175.97M | 186.91M | 132.2M | 186.01M | 189.07M | 220.83M | 225.27M | 225.17M |
Basic Shares Outstanding | 175.97M | 186.91M | 132.2M | 186.01M | 189.07M | 220.48M | 224.38M | 225.17M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
CVAC Balance Sheet
CureVac N.V. (CVAC) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 73.07M | 57.17M | 1.39B | 940.02M | 584.03M | 478.38M | 526.41M | 419.78M |
Cash & Short-Term Investments | 60.63M | 32.14M | 1.33B | 816.11M | 500.28M | 405.11M | 485.37M | 395.81M |
Cash Only | 21.38M | 30.68M | 1.32B | 811.46M | 495.8M | 402.45M | 481.75M | 392.7M |
Short-Term Investments | 39.25M | 1.46M | 2.62M | 4.65M | 4.49M | 2.66M | 3.62M | 3.11M |
Accounts Receivable | 6.86M | 17.15M | 1.82M | 53.74M | 9M | 39.51M | 32.9M | 7.7M |
Days Sales Outstanding | 194.48 | 359.49 | 13.6 | 190.45 | 48.74 | 268.26 | 22.44 | 12.9 |
Inventory | 2.95M | 6.2M | 14.53M | 56.16M | 23.99M | 24.8M | 541K | 541K |
Days Inventory Outstanding | 60.7 | 80.83 | 374.22 | 86.06 | 47.59 | 72.79 | 1.87 | 7.21 |
Other Current Assets | 0 | 0 | 0 | 8.29M | 15.81M | 7.88M | 6.81M | 15.72M |
Total Non-Current Assets | 52.59M | 73.44M | 121.5M | 218.22M | 276.44M | 309.87M | 276.41M | 269.1M |
Property, Plant & Equipment | 45.49M | 66.78M | 104.79M | 200.39M | 241.7M | 278.63M | 244.65M | 238.41M |
Fixed Asset Turnover | 0.28x | 0.26x | 0.47x | 0.51x | 0.28x | 0.19x | 2.19x | 2.12x |
Goodwill | 0 | 0 | 0 | 0 | 12.46M | 12.46M | 12.46M | 0 |
Intangible Assets | 6.21M | 5.7M | 14.15M | 13.24M | 19.32M | 15.88M | 12.69M | 7.7M |
Long-Term Investments | 749K | 0 | 1.03M | 515K | 0 | -4K | 0 | 0 |
Other Non-Current Assets | 1K | 967K | 1.09M | 1.22M | 1.67M | 1.7M | 1.51M | 1.51M |
Total Assets | 125.66M▲ 0% | 130.62M▲ 3.9% | 1.51B▲ 1057.1% | 1.16B▼ 23.4% | 860.47M▼ 25.7% | 788.25M▼ 8.4% | 802.83M▲ 1.8% | 688.88M▲ 0% |
Asset Turnover | 0.10x | 0.13x | 0.03x | 0.09x | 0.08x | 0.07x | 0.67x | 0.66x |
Asset Growth % | - | 3.95% | 1057.06% | -23.36% | -25.71% | -8.39% | 1.85% | 34.37% |
Total Current Liabilities | 28.13M | 28.09M | 247.62M | 357.73M | 156.22M | 186.39M | 72.35M | 68.02M |
Accounts Payable | 9.03M | 5.33M | 17.62M | 122.26M | 68.25M | 48.03M | 17.27M | 7.58M |
Days Payables Outstanding | 185.73 | 69.54 | 453.85 | 187.35 | 135.38 | 140.97 | 59.57 | 164.21 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 5.78M | 7.48M | 157.99M | 55.75M | 36.78M | 44.58M | 0 | 2.38M |
Other Current Liabilities | 11.92M | 11.84M | 55.58M | 171.38M | 44.69M | 88.74M | 31.5M | 37.3M |
Current Ratio | 2.60x | 2.04x | 5.61x | 2.63x | 3.74x | 2.57x | 7.28x | 6.17x |
Quick Ratio | 2.49x | 1.82x | 5.55x | 2.47x | 3.58x | 2.43x | 7.27x | 6.16x |
Cash Conversion Cycle | 69.45 | 370.78 | -66.03 | 89.15 | -39.06 | 200.08 | -35.26 | -144.1 |
Total Non-Current Liabilities | 65.45M | 145.34M | 552.39M | 112.03M | 170.99M | 84.92M | 33.87M | 34.49M |
Long-Term Debt | 0 | 65.02M | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 12.13M | 26.85M | 25.42M | 37.11M | 36.82M | 33.64M | 131.87M |
Deferred Tax Liabilities | 0 | 1.62M | 0 | 0 | 0 | 0 | 227K | 681K |
Other Non-Current Liabilities | 863K | 68.19M | 25.47M | 86.61M | 133.89M | 0 | 0 | 2.95M |
Total Liabilities | 93.58M | 173.42M | 800.01M | 469.77M | 327.22M | 271.31M | 106.22M | 102.51M |
Total Debt | 77K | 79.15M | 30.09M | 28.89M | 42.09M | 41.82M | 38.97M | 36.03M |
Net Debt | -21.3M | 48.46M | -1.29B | -782.57M | -453.71M | -360.63M | -442.78M | -356.67M |
Debt / Equity | 0.00x | - | 0.04x | 0.04x | 0.08x | 0.08x | 0.06x | 0.06x |
Debt / EBITDA | - | - | - | - | - | - | 0.20x | 0.16x |
Net Debt / EBITDA | - | - | - | - | - | - | -2.25x | -1.58x |
Interest Coverage | -264.81x | -68.15x | -5.61x | -39.88x | -67.29x | -109.99x | - | 547.87x |
Total Equity | 32.08M▲ 0% | -42.8M▼ 233.4% | 711.35M▲ 1761.9% | 688.48M▼ 3.2% | 533.25M▼ 22.5% | 516.94M▼ 3.1% | 696.61M▲ 34.8% | 586.37M▲ 0% |
Equity Growth % | - | -233.41% | 1761.95% | -3.22% | -22.55% | -3.06% | 34.76% | 155.4% |
Book Value per Share | 0.18 | -0.23 | 5.38 | 3.70 | 2.82 | 2.34 | 3.09 | 2.60 |
Total Shareholders' Equity | 32.08M | -42.8M | 711.35M | 688.48M | 533.25M | 516.94M | 696.61M | 586.37M |
Common Stock | 727K | 727K | 21.66M | 22.45M | 23.4M | 26.88M | 26.92M | 27.02M |
Retained Earnings | -416.07M | -515.95M | -645.07M | -1.06B | -1.31B | -1.57B | -1.4B | -1.52B |
Treasury Stock | 0 | 0 | 0 | -5.82M | -1.48M | 0 | 0 | 0 |
Accumulated OCI | 447.43M | 472.42M | 1.33B | 1.73B | 1.82B | 2.06B | 2.07B | 2.07B |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CVAC Cash Flow Statement
CureVac N.V. (CVAC) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -74.11M | -86.96M | 522.4M | -733.13M | -286.18M | -267.89M | 101.85M | 204.08M |
Operating CF Margin % | -575.79% | -499.33% | 1068.31% | -711.84% | -424.47% | -498.32% | 19.03% | - |
Operating CF Growth % | - | -17.34% | 700.72% | -240.34% | 60.96% | 6.39% | 138.02% | 727.86% |
Net Income | -71.13M | -100.13M | -129.85M | -412.5M | -249.16M | -260.17M | 190.88M | 193.64M |
Depreciation & Amortization | 3.78M | 7.16M | 10.67M | 15.67M | 23.74M | 23.39M | 18.81M | 17.8M |
Stock-Based Compensation | -4.25M | 19.56M | 14.24M | 14.96M | 9.19M | 7.7M | 4.12M | 5.08M |
Deferred Taxes | 52K | -847K | -2.87M | 199.02M | -1.58M | 0 | 0 | 0 |
Other Non-Cash Items | -1.48M | 9.93M | 51.63M | -480.74M | 57.2M | 29.49M | 52M | 47.01M |
Working Capital Changes | -1.08M | -22.65M | 578.57M | -69.55M | -125.56M | -68.29M | -163.96M | -86.2M |
Change in Receivables | -5.59M | -10.12M | -32.3M | -19.82M | -16.68M | -7.92M | 11.47M | 37.24M |
Change in Inventory | 878K | -3.25M | -8.33M | -227.46M | -47.85M | -46.96M | 590K | -84K |
Change in Payables | 9.4M | -9.58M | 620.3M | 179.32M | -96.19M | -29.37M | -140.58M | 0 |
Cash from Investing | -4.26M | 28.18M | -45.27M | -127.9M | -93.5M | -55.2M | -18.44M | -7.93M |
Capital Expenditures | -14.72M | -12.22M | -47.35M | -127.9M | -93.22M | -52.32M | -14.31M | -7.04M |
CapEx % of Revenue | 114.39% | 70.19% | 96.83% | 124.19% | 138.27% | 97.32% | 2.67% | 1.38% |
Acquisitions | 0 | 0 | 0 | 0 | -277K | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 5.14M | 2.33M | 3.24M | -3.68M | -5.2M | -2.88M | -4.13M | -894K |
Cash from Financing | -112K | 67.98M | 819.83M | 344.96M | 63.17M | 230.89M | -5.11M | -5.39M |
Debt Issued (Net) | -112K | 67.98M | -47.88M | -28.18M | -4.22M | -5.19M | -5.11M | -5.26M |
Equity Issued (Net) | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 0 | -138K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -30.91M | 0 | 0 | 0 | -69K |
Other Financing | 0 | 0 | 0 | 0 | 0 | 246K | 0 | -1K |
Net Change in Cash | -78.27M▲ 0% | 9.3M▲ 111.9% | 1.29B▲ 13785.5% | -511.13M▼ 139.6% | -315.67M▲ 38.2% | -93.34M▲ 70.4% | 79.3M▲ 184.9% | 190.19M▲ 0% |
Free Cash Flow | -88.83M▲ 0% | -99.19M▼ 11.7% | 475.05M▲ 578.9% | -861.03M▼ 281.2% | -379.4M▲ 55.9% | -323.09M▲ 14.8% | 83.41M▲ 125.8% | 196.15M▲ 0% |
FCF Margin % | -690.18% | -569.52% | 971.47% | -836.03% | -562.74% | -601% | 15.58% | 38.42% |
FCF Growth % | - | -11.66% | 578.94% | -281.25% | 55.94% | 14.84% | 125.82% | 160.27% |
FCF per Share | -0.50 | -0.53 | 3.59 | -4.63 | -2.01 | -1.46 | 0.37 | 0.87 |
FCF Conversion (FCF/Net Income) | 1.04x | 0.87x | -4.05x | 1.78x | 1.15x | 1.03x | 0.63x | 1.01x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CVAC Key Ratios
CureVac N.V. (CVAC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -38.61% | -58.82% | -40.77% | -49.55% | 26.73% | 33.02% |
Return on Invested Capital (ROIC) | -907.72% | - | - | -235.21% | -174.39% | 64.98% | 66.2% |
Gross Margin | -60.67% | 71.02% | -131.28% | -172.91% | -131.34% | 80.23% | 94.81% |
Net Margin | -573.46% | -263.95% | -399.76% | -369.37% | -483.96% | 30.3% | 37.93% |
Debt / Equity | - | 0.04x | 0.04x | 0.08x | 0.08x | 0.06x | 0.06x |
Interest Coverage | -68.15x | -5.61x | -39.88x | -67.29x | -109.99x | - | 547.87x |
FCF Conversion | 0.87x | -4.05x | 1.78x | 1.15x | 1.03x | 0.63x | 1.01x |
Revenue Growth | 35.31% | 180.78% | 110.61% | -34.54% | -20.26% | 895.54% | 682.03% |
Related:CVAC Dividend History·CVAC Revenue History·CVAC Price History·CVAC P/E History·CVAC Financial Ratios·CVAC Institutional Holders
CVAC Frequently Asked Questions
CureVac N.V. (CVAC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
CureVac N.V. (CVAC) reported $510.5M in revenue for fiscal year 2024. This represents a 3866% increase from $12.9M in 2018.
CureVac N.V. (CVAC) grew revenue by 895.5% over the past year. This is strong growth.
Yes, CureVac N.V. (CVAC) is profitable, generating $193.6M in net income for fiscal year 2024 (30.3% net margin).
Dividend & Returns
CureVac N.V. (CVAC) has a return on equity (ROE) of 26.7%. This is excellent, indicating efficient use of shareholder capital.
CureVac N.V. (CVAC) generated $196.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.